[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587367":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":111,"collaborators":11,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":11,"eligibilityCriteria":118,"healthyVolunteers":115,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":11,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"B019","EXPERIMENTAL",null,[13],"Biological: B019",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","B019： Intravenous infusion, 1.0×10\\^6 CAR T cell\u002Fkg-10.0×10\\^6 CAR T cell\u002Fkg",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Jing Chen","CONTACT","0086-021-38626161","chenjing@scmc.com.cn",[26,41,52,60,71,78,89,100],{"facility":27,"status":28,"city":29,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Peking University People's Hospital","RECRUITING","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":11,"phoneExt":11,"email":11},"Yifei Cheng",{"facility":42,"status":28,"city":43,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Jiangxi Province pediatric hospital","Nanchang",{"type":33,"coordinates":45},[46,47],115.85306,28.68396,{"lat":47,"lon":46},[50],{"name":51,"role":22,"phone":11,"phoneExt":11,"email":11},"Fei He",{"facility":53,"status":28,"city":43,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"The First Affiliated Hospital of Nanchang University",{"type":33,"coordinates":55},[46,47],{"lat":47,"lon":46},[58],{"name":59,"role":22,"phone":11,"phoneExt":11,"email":11},"Fei Li",{"facility":61,"status":28,"city":62,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Children's Hospital of Shanghai","Shanghai",{"type":33,"coordinates":64},[65,66],121.45806,31.22222,{"lat":66,"lon":65},[69],{"name":70,"role":22,"phone":11,"phoneExt":11,"email":11},"Jingbo Shao",{"facility":72,"status":28,"city":62,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"Shanghai Children's Medical Center",{"type":33,"coordinates":74},[65,66],{"lat":66,"lon":65},[77],{"name":21,"role":22,"phone":11,"phoneExt":11,"email":11},{"facility":79,"status":28,"city":80,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Children's Hospital of Soochow University","Suzhou",{"type":33,"coordinates":82},[83,84],120.59538,31.30408,{"lat":84,"lon":83},[87],{"name":88,"role":22,"phone":11,"phoneExt":11,"email":11},"Shaoyan Hu",{"facility":90,"status":28,"city":91,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Tongji Hospital","Wuhan",{"type":33,"coordinates":93},[94,95],114.26667,30.58333,{"lat":95,"lon":94},[98],{"name":99,"role":22,"phone":11,"phoneExt":11,"email":11},"Jia Kui",{"facility":101,"status":28,"city":102,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou",{"type":33,"coordinates":104},[105,106],117.28386,34.20442,{"lat":106,"lon":105},[109],{"name":110,"role":22,"phone":11,"phoneExt":11,"email":11},"Zhenyu Li",{"type":112,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100587367","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-b019-injection-in-subjects-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-100587367",false,"NCT06927466","A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.","Inclusion Criteria:\n\n1. The patient himself\u002Fherself , and\u002For his\u002Fher legal guardian, agree to participate in the trial and sign the informed consent form；\n2. Meet the diagnostic criteria for recurrent or refractory acute B cell lymphoblastic leukemia；\n3. Documentation of CD19\u002FCD22 tumor expression\n\n3\\. Liver, kidney, lung and heart function meet requirements; 4. Expected survival \\>3 months; 5. Women of childbearing age and all post-adolescent male participants are willing to use highly effective contraceptive methods within 1 year after the infusion of B019 injection. At the same time, the subject should promise not to donate eggs or sperm for assisted reproduction for 1 year after the cell infusion.\n\n\\-\n\nExclusion Criteria:\n\n1. Active CNS involvement by malignancy；\n2. Isolated extramedullary leukemia recurrence；\n3. Subjects with ≥grade 2 acute or moderate to severe chronic graft-versus-host disease (GVHD) within 4 weeks prior to screening;\n4. Has had treatment with any prior CAR-T therapy or other therapy abandoned in protocal.\n\n4\\. Subjects who received therapy abandoned in protocal before PBMC (peripheral blood mononuclear cells) collection or before B019 injection; 5.Active other malignancy in 5 years. 6. Subjects who are positive for any of HBsAg, HBeAg, HBeAb, HBcAb, HCV-RNA, HIV EBV DNA, CMV DNA, HTLV-ab.\n\n7\\. Other situations deemed inappropriate for participation in this study by the investigator.\n\n\\-","ALL","3 Years","25 Years",{"count":123,"type":124},33,"ESTIMATED","INTERVENTIONAL",[127],"PHASE1","The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.",[130],"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","2025-05-21",{"date":133,"type":134},"2025-05-22","ACTUAL",{"date":136,"type":134},"2024-09-19",{"date":138,"type":124},"2028-06-30",{"name":5,"class":6},8]